Skip to main content

Increasing FDA approval for thyroid cancer drug is expected to present profitable market opportunities

 


Thyroid disorder therapy is a fast-growing area of treatment for people suffering from this condition. The thyroid gland is responsible for regulating metabolism and temperature, with control through the use of the thyroid gland located in the neck just below the voice box. A person suffering from Thyroid disorder have signs and symptoms such as weight gain, fatigue, depression, and constipation. Thyroid Dysfunction may be caused by many factors, and the causes and symptoms are different in every person. Thyroid disease is a highly treatable condition if diagnosed early enough, although treatment options will vary from person to person depending on their age, overall health, and underlying health problems.

The growing prevalence of thyroid disorder around the globe is a prime factor driving the market growth of thyroid disorder therapy. According to the American Thyroid Association (ATA), an estimated 20 million Americans have some form of thyroid disease. Up to 60 percent of those with thyroid disease are unaware of their condition. Women are five to eight times more likely than men to have thyroid problems. The increasing geriatric population coupled with the rise in the global healthcare expenditure is again expected to augment the market growth of thyroid disorder therapy.

North America is expected to gain significant growth over the forecast period and this is attributed to the increasing prevalence of thyroid cancer coupled with the continuous FDA approval for the new and advanced drug. For instance, in December 2020, the Food and Drug Administration approved pralsetinib (GAVRETO, Blueprint Medicines Corporation) for RET-altered thyroid cancers. Moreover, increasing spending by the government on cancer treatment for improving patient care is further anticipated to augment the regional market growth of thyroid disorder therapy over the forecast period.

Key Developments:

1.      In October 2020, BDR Pharmaceutical announced the launch of 4 mg and 10 mg of Lenvatinib under the brand name BDFOIE for the treatment of differentiated thyroid cancer, advanced liver cancer, and advanced kidney cancer.

2.      In July 2020, Roche and its Genentech subsidiary announced its partnership with Blueprint Medicines to develop and commercialize the once-daily oral cancer drug pralsetinib in most of the world.

3.      In May 2018, FDA has approved Novartis’ combination treatment dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of BRAF V600 mutation-positive anaplastic thyroid cancer (ATC) that cannot be removed by surgery or is metastatic.

 

 

 

 

 

Comments

Popular posts from this blog

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

  A primary driver for this market is the worldwide increase in occurrence of diabetes and cancer, across all age groups. According to the World Health Organization (WHO) 2018 statistics, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. Moreover according to the World Health Organization cancer factsheet 2018, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018.  Furthermore, increasing old age population is another driver, which is anticipated to create a high growth scenario for the market. As per the World Population Prospects 2019 revision, the number of people aged 80 years or over is projected to be triple, from 143 million in 2019 to 426 million in 2050. Alternatively, factors restraining the market are complications and risks associated with the treatment including diarrhea, nausea, hair loss, vomiting, severe infections, infertility, and heart complications....

North America is expected to lead the global cosmetology market due to growing number of minimally invasive surgeries in the region

  Market Overview: Cosmetology is the field of a beauty practice that includes a variety of practices aimed at making individual’s look and feel their best. Competitive Landscape: GC Aesthetics, Mentor Worldwide LLC, Sientra Inc., Zimmer Holdings Inc., 3M Health Care, Allergan, Inc., Implantech Associates Inc., Institut Straumann AG, Nobel Biocare Holding AG, and Spectrum Designs Medical.   Key Market Drivers: An increasing number of cosmetic surgeries is expected to expand the global cosmetology market size. For instance, according to American Society of Plastic Surgeons (ASPS) 2017 reports, around 17.5 million cosmetic surgeries were performed in 2017, U.S. among which breast augmentation, liposuction, and nose reshaping were the top three procedures. High preferences for Botox surgeries which are used to reduce wrinkles and maintain youthful skin is again fostering the growth of the market growth. According to the same source, around 65% of women prefer Botul...

Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market is Expected to Grow Drastically, Assured By Experts From 2023 To 2028

  Surgical hemostat is a surgical tool used in many surgical procedures to control bleeding. Surgical hemostats covered in this report include thrombin-based, combination hemostats, oxidized regenerated cellulose-based, gelatin-based, and collagen-based. Internal tissue sealants are typically used in surgeries to bind or hold internal tissues such as blood vessels, internal organs, bone cartilage, dura matter and others. The global surgical hemostats, internal tissue sealants and adhesion barriers market is estimated to account for US$ 4,231.4 Mn in terms of value in 2020 and is expected to reach US$ 7,346.7 Mn by the end of 2027 Global Surgical Hemostats, Internal Tissue Sealants and Adhesion Barriers Market: Drivers Increasing number of surgical procedures is expected to propel growth of the global surgical  hemostats , internal tissue sealants and adhesion barriers market over the forecast period. For instance, according to ‘Surgical operations and procedures sta...